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Abstract
Background: To meet emergent healthcare needs, innovations need to be implemented into routine clinical practice.
Community pharmacy is increasingly considered a setting through which innovations can be implemented to achieve
positive service and clinical outcomes. Small-scale pilot programmes often need scaled up nation-wide to affect
population level change. This systematic review aims to identify facilitators and barriers to the national implementation
of community pharmacy innovations.
Methods: A systematic review exploring pharmacy staff perspectives of the barriers and facilitators to implementing
innovations at a national level was conducted. The databases Medline, EMBASE, PsycINFO, CINAHL, and Open Grey
were searched and supplemented with additional search mechanisms such as Zetoc alerts. Eligible studies underwent
quality assessment, and a directed content analysis approach to data extraction was conducted and aligned to the
Consolidated Framework for Implementation Research (CFIR) to facilitate narrative synthesis.
Results: Thirty-nine studies were included: 16 were qualitative, 21 applied a questionnaire design, and 2 were mixed
methods. Overarching thematic areas spanning across the CFIR domains were pharmacy staff engagement (e.g. their
positive and negative perceptions), operationalisation of innovations (e.g. insufficient resources and training), and
external engagement (e.g. the perceptions of patients and other healthcare professionals, and their relationship with
the community pharmacy). Study participants commonly suggested improvements in the training offered, in the
engagement strategies adopted, and in the design and quality of innovations.
Conclusions: This study’s focus on national innovations resulted in high-level recommendations to facilitate the
development of successful national implementation strategies. These include (1) more robust piloting of innovations,
(2) improved engagement strategies to increase awareness and acceptance of innovations, (3) promoting whole-team
involvement within pharmacies to overcome time constraints, and (4) sufficient pre-implementation evaluation to gauge
acceptance and appropriateness of innovations within real-world settings. The findings highlight the international challenge
of balancing the professional, clinical, and commercial obligations within community pharmacy practice. A preliminary
theory of how salient factors influence national implementation in the community pharmacy setting has been developed,
with further research necessary to understand how the influence of these factors may differ within varying contexts.
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Background
A strong primary care system underpins improvements in
a nation’s population health [1, 2]; therefore, the primary
care sector must continually adapt to meet emergent
healthcare needs. Community pharmacies have veered
away from traditional dispensing-focused roles as their
ability to offer enhanced services within primary care has
been recognised [3]. Existing contributions within primary
care include the administration of vaccinations [4], smok-
ing cessation support [5], and medication reviews [6, 7].
Additionally, the introduction of pharmacy technicians
performing accuracy checks on dispensed medication and
the implementation of novel technologies, such as auto-
mated dispensing, are considered facilitators to improve
efficiency and workflow [8, 9]. This can allow pharmacies
more time to offer more patient-focused services.
Access to a healthcare professional without the need for
an appointment renders community pharmacies unique to
other primary care settings, which enhances the scope of
exposure of new services to more patients [10–12]. Suc-
cessful implementation of innovations within healthcare
systems underpins the achievement of intended out-
comes—for example, improvements in efficiency, safety, or
symptomology [13]. For maximal impact within primary
care, and to improve population-level health, innovations
need scaled up nation-wide [14].
The complexity of national implementation is well
acknowledged [15]. Within community pharmacies, ser-
vice delivery can be dependent on ownership [16], partly
due to the autonomous nature of community pharma-
cies and their requirement to be profitable. Wide-scale
implementation is further complicated as barriers and
facilitators identified within small-scale, pilot phases may
not be generalisable to the national setting [17]. This
may be due to the recruitment of “early adopters” who
may be less resistant to change [18, 19].
Two previous reviews have explored implementation
within the community pharmacy setting. Organisational
and individual facilitators to practice change in relation
to cognitive pharmacy services have been identified by
Roberts et al. [20]. As few empirical studies at this time
explored implementation, the results are mostly centred
on hypothetical facilitators. More recently, Shoemaker
et al. identified barriers and facilitators to the implementa-
tion of three services common in the USA (Medication
Therapy Management, immunisations, and rapid HIV
testing) [21]. However, methodological approaches
adopted by these reviews and associated limitations war-
rant further exploration within this area. The reviews by
Shoemaker et al. and Roberts et al. explored barriers and
facilitators only for a subset of innovation types. Neither
focused specifically on national innovations and included
those limited to pilot stages. Additionally, neither critically
appraised the included studies, and the reviews included
studies which sought perspectives from individuals with
no involvement in implementation, meaning the results
may not reflect barriers and facilitators truly experienced
in practice.
Considering the evolving role of the community phar-
macy setting, and the uniqueness of this context, further
exploration is required to understand how innovations
in this setting can be scaled up to affect nationwide im-
provements in health. This systemic review addresses
this to identify barriers and facilitators to the national
implementation of community pharmacy innovations by
building upon the reviews previously conducted and
overcoming their associated limitations [20, 21]. The
objectives of this systematic review are to:
1. Identify studies exploring the factors influencing
the national implementation of community
pharmacy innovations from the perspectives of
community pharmacy staff
2. Synthesise reported barriers and facilitators
3. Develop recommendations for national
implementation strategies
Following completion of the systematic review, the
opportunity was recognised to develop a preliminary causal
theory of how innovations become successfully implemented
within community pharmacies at a national level. Therefore,
an additional objective was derived:
4. Develop a causal theory of the factors influencing
successful national implementation of community
pharmacy innovations
Methods
This systematic review is presented according to the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) 2009 checklist [22]. A protocol
was developed [23, 24] and uploaded onto the PROSPERO
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register of systematic reviews (Registration number:
CRD42016038876) [25].
Eligibility criteria
Eligible studies sought pharmacy staff ’s perspectives on
barriers and facilitators to implementing national innova-
tions. An innovation was considered a practice, object, or
idea perceived to be new to the setting in which it was
implemented [18]. Implementation was considered the
process by which an innovation was introduced and
applied within the pharmacy setting [26, 27]. Studies solely
focusing on views of adoption prior to the implementation
of an innovation were outwith the scope of this review as
this was considered the preliminary decision-making
process of the pharmacy staff to use an innovation [18],
which was considered conceptually dissimilar to imple-
mentation. Studies involving participants from mixed disci-
plines (e.g. general practitioners as well as community
pharmacy staff) were included if it was possible to extract
the data solely pertaining to community pharmacy staff
perspectives. Studies from any country were considered
eligible for inclusion. Qualitative, quantitative, and mixed
method studies were included from peer-reviewed journal
articles, conference proceedings, poster presentations, and
unpublished literature. The exclusion criteria are presented
in Table 1.
Search strategy
The databases Medline, EMBASE, PsycINFO, and the
Cumulative Index of Nursing and Allied Health Litera-
ture (CINAHL) were searched from their inception on
17 December 2015. Unpublished literature was searched
within the Open Grey database [28]. See Additional file 1
for the full Medline search strategy. The search was
limited to the English language and covered all studies
available up until the search date. Supplementary
searches were applied from December 2015 onwards
until data analysis concluded in March 2017 (Table 2).
Study selection
Titles and abstracts were screened within Covidence [29],
with potentially relevant studies progressing onto full-text
screening. The primary reviewer (NW) completed the
study selection, with a 20% subset of the title/abstracts
and full-texts screened independently. A percentage of
agreement was calculated and categorised using the fol-
lowing thresholds: < 70%, poor; 70–79%, fair; 80–89%,
good; and > 90%, excellent [30]. A percentage of agree-
ment > 80% was considered adequate [31]. Where the data
were published in more than one format, the format
which underwent the most extensive peer-review process
was included (e.g. a journal article would be selected for
data extraction over a conference proceeding).
Data extraction
A data extraction table was devised [24] and piloted in
approximately 10% of studies. Piloting identified that
delineating the data to barriers and facilitators was over-
simplistic as the studies also reported on suggestions of
what would have facilitated implementation. These were
termed “hypothetical facilitators” and were extracted
separately.
Quality assessment
Quality assessment tools were used specific to the
method(s) employed. This was to ensure that existing pur-
posefully designed tools were used to assess the quality of
either qualitative, quantitative, or mixed method studies to
comparable depth. They consisted of a series of questions
exploring aspects such as the clarity of the aim, appropri-
ateness of the methodology, recruitment of participants,
and data analysis. The 34-item Critical Appraisal Skills
Table 1 Exclusion criteria
• Studies reporting undefined innovations (e.g. concepts such as
“pharmaceutical care”)
• Studies exploring barriers and facilitators to implementing
innovations for specific pharmacy characteristics (e.g. barriers to
implementation within independently-owned pharmacies)
• Studies exploring barriers and facilitators to delivering services to a
specific subset of eligible patients (e.g. barriers to delivering medication
review services to aboriginal populations specifically)
• Studies exploring anticipated barriers or facilitators during pre-
implementation phases
• Books, editorials, lecture commentaries, and studies reporting
non-original research.
Table 2 Supplementary search strategy (December 2015–
March 2017)
1. Screening the reference list of included studies
2. Email alerts from the Zetoc database (a monitoring and search service
for global research publications) when new articles were published in
the following journals:
• Accreditation and Quality Assurance
• BMC Health Services Research
• BMJ Quality and Safety
• Implementation Science
• International Journal for Quality in Health Care
• International Journal of Health Care Quality Assurance
• International Journal of Pharmacy Practice
• International Journal of Quality And Innovation
• Joint Commission Journal on Quality and Patient Safety
• Quality Management in Health Care
• Research in Social and Administrative Pharmacy
3. Hand searches of The Pharmaceutical Journal
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Programme (CASP) tool was used to appraise qualitative
studies [32]. For questionnaire design studies, the Boynton
and Greenhalgh Quality Checklist (BGQC) tool was used
[26]. The mixed method studies all applied interviews
alongside a questionnaire. Existing mixed method quality
assessment tools did not assess questionnaires to the same
depth as the BGQC tool [33] and would not offer compar-
able quality assessment. Therefore, the mixed method
studies were assessed using the initial screening questions
within the Mixed Methods Appraisal Tool (MMAT) [34],
which explores the appropriateness of the mixed method
approach, with each method then assessed by the CASP or
BGQC tool [26, 32].
The quality assessment tools each have screening
questions on the clarity of the aim and appropriateness
of the research design. Studies were excluded if these
initial criteria were not met. Questionnaire studies which
used only closed-ended questions were excluded unless
based on previous qualitative work or wider literature as
the researchers would have introduced bias based on
their a priori assumptions of influential factors [35]. To
generate the quality assessment result for each study,
each question within the quality assessment tool was
attributed a score of 2 if the study fully met the criteria,
1 if partially met, and 0 if not met or unclear. The qual-
ity assessment results are presented as percentages as
not all questions were applicable to every study [32, 36].
The quality assessment results for the mixed method
studies were calculated from the lowest scoring method
to ensure the final result did not exceed the quality of
the studies weakest component [34]. The quality assess-
ment was conducted by the primary reviewer (NW),
with clarification from a mediator when required (ED).
Synthesis of results
The Consolidated Framework for Implementation Research
(CFIR) was selected to synthesise the data [37]. The CFIR is
a determinant implementation framework of factors influ-
encing implementation amongst five domains: intervention
characteristics, the inner setting, the outer setting, charac-
teristics of the individual, and the implementation process
[38]. It is widely applied [39], commonly to explore health-
care practitioners’ experiences of implementing an
innovation [40], which facilitates cross comparison of
results [41]. Each CFIR domain has a number of constructs
which are defined in Additional file 2.
A directed content analysis approach [42] was applied
where data extraction was conducted inductively, with
the synthesis afterwards deductively aligned to the CFIR
[43, 44]. This allowed data capture of barriers and facil-
itators not within the CFIR to test its applicability
within the community pharmacy context. As the CFIR
constructs are conceptually broad (e.g. one construct is
“Knowledge and Beliefs”), data within each CFIR
construct was explored for emergent subconstructs
[45]. A table quantifying the emergence of barriers, fa-
cilitators, and hypothetical facilitators within each CFIR
construct was developed, with overarching thematic
areas identified from visual analysis [45]. A descriptive
narrative synthesis method was chosen to present com-
monly reported CFIR constructs to facilitate integration
of qualitative and quantitative results [46–48].
To examine the robustness of the results, a sensitivity
analysis involved removal of studies with a quality as-
sessment result of < 50% to observe what effect this had
on the reporting frequency of the barriers, facilitators,
and hypothetical facilitators [49]. As different studies
evaluated the same innovation, the results were
categorised both by study and by innovation to see how
this affected reporting frequency.
Results
Study selection
Thirty-nine studies were included from the 5874
studies which had titles and abstracts screened (Fig. 1)
[6, 50–87]. The percentage of agreement of the titles
and abstracts independently screened was 94% (excel-
lent), and for full-texts was 88% (good).
Study characteristics
All studies were published from 2002 onwards, and
most since 2010 (n = 28, 72%). Approximately half (n =
20, 51%) originated from the UK. Ten studies origi-
nated from other European countries, and the other
nine were from Australia (n = 3), Malaysia (n = 2), New
Zealand (n = 2), Saudi Arabia (n = 1), and Cambodia
(n = 1). The innovation types can be categorised into
four subtypes: clinical service (n = 21); pharmacovigi-
lance (n = 6); e-technology (n = 2); and legislative change
(n = 10) such as policy changes and reclassification of medi-
cines. Some studies evaluated the same innovation: the UK
“Healthy Living Pharmacy” framework (n = 5), the UK
“New Medicines Service” (n = 3), the “Danish’ Inhaler Tech-
nique Assessment Service” (n = 2), the UK “Medicines Use
Review” (n = 3), the Malaysian spontaneous adverse drug
reporting system “MADRAC” (n = 2), and the Swedish im-
plementation of ePrescribing (n = 2). Resultantly, the 39
studies report on 28 innovations. Excluding one study
which did not provide participant numbers [69], the total
number of participants included from the studies is 12,172.
Only ten studies (26%) explored perspectives of community
pharmacy support staff [52, 54, 57, 61, 63, 69, 70, 75, 82,
83], and two did so exclusively [57, 82]. The full characteris-
tics of included studies are within Additional file 3.
Quality assessment results
An overview of the quality assessment results is within
Table 3, with the full quality assessment in Additional file 4.
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Five studies were excluded as they applied questionnaires
with only closed-ended questions which were not reported
to be developed from reference to literature or previous
qualitative findings [88–92].
Qualitative studies
All qualitative studies (n = 16) detailed the research
aims and rationalised the study’s importance and rele-
vance. Six justified why a qualitative design was
chosen [54, 55, 60, 70, 77, 83], and three justified the
specific method adopted [61, 69, 77]. For one study
which employed two qualitative methods, only one
method was explicitly justified [74]. Six studies made the
methods fully explicit by including the interview or focus
group guide [52, 55, 57, 61, 74, 77]. No studies offered a
full account of reflexivity as none adequately considered
the researcher-participant relationship, although some
reflected on potential bias during data collection and sam-
pling [57, 62, 77, 82]. No study sufficiently discussed the
credibility of their findings as per the quality assessment
criteria.
Questionnaire design studies
All questionnaire design studies (n = 21) had a clear re-
search question. Six studies did not attain a response
rate of > 50% [59, 65, 76, 78, 79, 86], and three employed
sampling methods which made it not possible to deter-
mine response rates [50, 63, 80]. Two studies sampled a
single pharmacy chain [72, 73], and six sampled partici-
pants within specific geographical locations [51, 58, 59,
63, 68, 81]. Twelve studies piloted the questionnaire in a
representative cohort [6, 51, 58, 59, 64–67, 78–80, 86].
Four studies did not offer sufficient detail to determine if
the pilot sample was representative of study participants
[50, 63, 68, 85], and for one study, the pilot sample was not
representative [72]. One study modified an existing ques-
tionnaire without re-piloting it [73], and three studies did
not state if the questionnaire was piloted [71, 76, 81]. Three
studies had claims for both validity and reliability [51, 59,
80], ten had claims for neither [6, 50, 58, 63, 65, 67, 68, 71,
73, 85], and the remaining eight conducted face and/or
content validity testing [64, 66, 72, 76, 78, 79, 81, 86].
Mixed method studies
The mixed method studies were low in quality due to in-
sufficient details as both were conference proceedings
[53, 84]. One study did not explain the rationale for inte-
grating qualitative and quantitative methods [53], and
neither described how the data was integrated [53, 84].
Fig. 1 Flow chart of screening process to identify relevant studies (December 2015–March 2017)
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Barriers, facilitators, and hypothetical facilitators
The reporting frequency of the barriers, facilitators, and
hypothetical facilitators aligned to the CFIR constructs is
shown in Table 4. A full presentation of constructs and sub-
constructs is in Additional file 5. When removing studies
with a quality assessment score of < 50% (n = 12, 41%), no
changes were identified to the most commonly reported
CFIR constructs amongst the barriers, facilitators, and
hypothetical facilitators. Likewise, when categorising results
by innovation and not by study, the most commonly re-
ported CFIR constructs remained the same. Therefore, for
completeness, all studies were retained within the analysis.
Thirteen (33%) CFIR constructs were cited by at least
ten studies (25%) as a barrier, facilitator, or hypothetical
facilitator. Overarching thematic areas spanning across the
CFIR domains were identified: pharmacy staff engagement,
operationalisation of the innovation, and external engage-
ment (Table 5).
Pharmacy staff engagement
Knowledge and beliefs about the intervention Positive
and negative views of the innovation by the pharmacy
staff were commonly cited factors influencing imple-
mentation. Nine studies had mixed views from partici-
pants [52, 55, 57, 62, 72, 73, 78, 85, 86]. The negative
perceptions were varied and in many instances context
specific, but included concerns and a lack of belief in/
support for the innovation [51, 52, 55, 57–60, 62, 66, 69,
72–74, 78, 80, 85–87]. Positive perceptions included a
belief in/support for the innovation [6, 50–52, 55–62,
67, 68, 72, 73, 75, 78, 85, 86] and positivity about the
way the innovation was implemented [84].
In four studies, good awareness and understanding
surrounding the innovation were cited [52, 62, 68, 85].
Notably for two of these, lack of knowledge was also
cited by some participants [62, 85]. Lack of awareness
[51, 59, 60, 68, 84] and operational knowledge [51, 57–
60, 62, 68, 76, 84, 85] was common, and lack of appro-
priate clinical knowledge was cited by five studies [51,
58, 59, 70, 85]. All pharmacovigilance studies cited a lack
of awareness and knowledge [51, 58–60, 68, 85].
Compatibility—with roles/values An innovation’s com-
patibility with the roles and values of a pharmacist was
reported. This included alignment with ambitions [78],
Table 3 Summary of quality assessment results of included
studies (n = 39)
Qualitative studies
(n = 16)
Result
(%)
Questionnaire design studies
(n = 21)
Result
(%)
Mixed method studies
(n = 2)
Result
(%)
Chaar 2013* [55] 74 Chee Ping 2010* [80] 79 Thomas 2009^[84] 25
Lucas 2015* [77] 71 Duarte 2015* [58] 76 Blenkinsopp 2007^[53] 19
Donovan 2016* [57] 70 Bawazir 2006* [51] 74
Rutter 2015* [82] 68 Hamrosi 2014* [65] 70
Kaae 2010* [69] 66 Elkalmi 2014* [59] 68
Bell 2012* [52] 65 Paudyal 2010* [79] 68
Kaae 2011* [69] 65 Kansanahoa 2005* [71] 65
Firth 2015* [61] 63 Paudyal 2012* [78] 64
Gauld 2011* [62] 63 Weidmann 2011* [86] 64
Elkalmi 2011* [60] 62 Hansford 2007* [66] 64
Latif 2016* [74] 62 Hammar 2010* [64] 61
Brooks 2013* [54] 47 Van Grootheest 2002* [85] 62
Wilcock 2008* [87] 42 Irujo 2007* [68] 57
Longergan 2012^ [75] 41 Latif 2008* [72] 55
Shevket 2015^ [83] 35 Rahimi 2011* [81] 50
Corlett 2013^ [56] 33 Gröber-grätz 2010* [63] 50
Lee 2008* [6] 48
Allenet 2003*[50] 38
Latif 2010^ [73] 37
Loo 2011^ [76] 31
Hodson 2014^ [67] 29
*Peer-reviewed journal paper
^Conference abstract
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Table 4 Frequency table of cited Consolidated Framework for Implementation Research (CFIR) constructs (n = 39 studies)
CFIR domains (n = 5) and constructs (n = 39) Barrier n (%) of studies Facilitator n (%) of studies Hypothetical facilitator n (%) of studies
Intervention Characteristics
Intervention source 0 (0) 0 (0) 0 (0)
Evidence strength and quality 1 (3) 0 (0) 0 (0)
Relative advantage* 7 (18) 12 (31) 0 (0)
Adaptability 7 (18) 1 (3) 2 (5)
Trialability 0 (0) 0 (0) 0 (0)
Complexity* 12 (31) 2 (5) 3 (8)
Design quality and packaging* 10 (26) 2 (5) 11 (28)
Cost 6 (15) 0 (0) 0 (0)
Outer setting
Patient needs and resources* 21 (54) 9 (23) 0 (0)
Cosmopolitanism* 15 (38) 4 (10) 5 (13)
Peer pressure 0 (0) 0 (0) 1 (3)
External policy and incentives* 6 (15) 2 (5) 11 (28)
Inner setting
Structural characteristics 0 (0) 3 (8) 0 (0)
Networks and communications 2 (5) 2 (5) 0 (0)
Culture 0 (0) 0 (0) 0 (0)
Implementation climate
Tension for change 1 (3) 0 (0) 0 (0)
Compatibility* 9 (23) 12 (31) 1 (3)
Relative priority 3 (8) 0 (0) 0 (0)
Organisational incentives and rewards* 1 (3) 15 (38) 0 (0)
Goals and feedback 2 (5) 2 (5) 6 (15)
Learning climate 0 (0) 0 (0) 0 (0)
Readiness for implementation
Leadership engagement 3 (8) 2 (5) 0 (0)
Available resources* 28 (72) 7 (18) 10 (26)
Access to knowledge and information* 8 (21) 5 (13) 17 (44)
Characteristics of individuals
Knowledge and beliefs about the intervention* 22 (56) 21 (54) 0 (0)
Self-efficacy 4 (10) 6 (15) 0 (0)
Individual stage of change 6 (15) 9 (23) 0 (0)
Individual identification with organisation 0 (0) 0 (0) 0 (0)
Other personal attributes 4 (10) 5 (13) 0 (0)
Process
Planning 1 (3) 0 (0) 3 (8)
Engaging
Engaging stakeholders*^ 1 (3) 0 (0) 12 (31)
Engaging innovation participants*^ 3 (8) 1 (3) 12 (31)
Opinion leaders 0 (0) 0 (0) 0 (0)
Formally appointed internal opinion leaders 0 (0) 0 (0) 0 (0)
Champions 0 (0) 0 (0) 0 (0)
External change agents 0 (0) 0 (0) 0 (0)
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the innovation recognising the potential of the pharmacy
profession to adopt enhanced or professional roles [61,
74], or being considered integral to a pharmacist’s role
[51, 56, 59, 60, 68, 85, 87].
Relative advantage An innovation offering an advan-
tage was evident within 12 studies [50, 54, 61, 64, 75, 77,
79–81, 83, 85, 87]. General advantages included en-
hanced engagement or relationship with patients [50, 61,
79, 87]; improvement in workforce capability, such as
improved education, awareness, or confidence [54, 61,
75, 85]; better relationship with surrounding healthcare
professionals [79, 83]; and the innovation benefitting pa-
tients [64, 75, 77, 79, 80, 83]. Some were context spe-
cific, for example, the time-saving aspect of the Swedish
ePrescribing system [64, 81], and the Scottish Minor
Ailments Service [79] meaning product cost is no longer
considered during consultations [79]. Six studies
reported that the innovation presented disadvantages
[55, 62–64, 79, 81], and three cited both advantages and
disadvantages of an innovation [64, 79, 81].
External policy and incentives This construct relates
to policy and incentives originating from government or
other central entities [93]. In relation to external policy,
reported barriers included the innovation not being
aligned with policy [65]. Studies suggested hypothetical
facilitators including extending the scope of innovations
[6, 52, 65] and making participation in pharmacovigi-
lance innovations compulsory [51, 58, 60, 85]. In relation
to external incentives, lack of/insufficient funding [6, 83]
or remunerations [50, 76, 79] were reported barriers.
Suggestions of incentives which could facilitate imple-
mentation were primarily financial [50–52, 60, 65, 72,
76, 85], but also included the provision of awards, certi-
fications, journal subscription, and conference attend-
ance [60] or penalising other healthcare professionals for
lack of co-operation [50].
Organisational incentives and rewards This CFIR con-
struct relates to incentives and rewards originating from
specific pharmacy organisations, as well personal incen-
tives of the community pharmacy staff [93]. One study
cited negative perceptions of target setting within the
pharmacy, which were perceived as income-focused rather
than patient-focused [87]. For clinical services and legisla-
tive changes, personal rewards included improved profes-
sional recognition [50, 56, 61, 79], enhanced influence or
role [50, 72, 77–79, 86], and personal or professional satis-
faction [52, 56, 74, 76, 82]. Commercial benefits spanned
across all innovations, including financial betterment for
the pharmacy [57, 61, 64, 78, 79] and increased customer
footfall [52, 83].
Table 5 Overarching thematic areas identified from included studies (n = 39) across commonly reported Consolidated Framework
for Implementation Research (CFIR) constructs
Thematic areas Description CFIR construct (CFIR domain)
Pharmacy staff
engagement
Pharmacy staff’s knowledge and beliefs relating to an innovation,
its compatibility with their roles and values, whether it poses
advantages or not, and the incentives and strategies which
engage community pharmacy staff.
• Knowledge and beliefs about the
intervention (characteristics of individuals)
• Compatibility—with roles or values
(inner setting)*
• Relative advantage (innovation characteristics)
• External policy and incentives (outer setting)
• Organisational incentives and rewards (inner setting)
• Engaging innovation participants (process)
Operationalisation
of the innovation
Innovation attributes (such as design and complexity) and
surrounding factors including resources, compatibility with
pharmacy systems, and pharmacy staff access to knowledge
and information about the innovation.
• Available resources (inner setting)
• Design quality and packaging (innovation characteristics)
• Complexity (innovation characteristics)
• Compatibility—with systems (inner setting)*
• Access to knowledge and information (inner setting)
External
engagement
The relationship with patients and other healthcare professionals,
their perceptions, and strategies to engage these stakeholders.
• Cosmopolitanism (outer setting)
• Patient needs and resources (outer setting)
• Engaging stakeholders (process)
*The compatibility construct of the CFIR was delineated into “Compatibility—with roles and values” and “Compatibly—with systems”
Table 4 Frequency table of cited Consolidated Framework for Implementation Research (CFIR) constructs (n = 39 studies)
(Continued)
CFIR domains (n = 5) and constructs (n = 39) Barrier n (%) of studies Facilitator n (%) of studies Hypothetical facilitator n (%) of studies
Executing 0 (0) 0 (0) 1 (3)
Reflecting and evaluating 0 (0) 0 (0) 1 (3)
*Represents CFIR constructs cited by at least ten studies (25%) as a barrier, facilitator, or hypothetical facilitator
^The CFIR construct “Engaging” has been subdivided into “Engaging Stakeholders” and “Engaging Innovation Participants” as per the CFIR qualitative codebook
guidelines (https://cfirguide.org/constructs/engaging/)
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Engaging innovation participants There was little data
pertaining to how the implementation strategy influ-
enced implementation. Better informing and engaging
the pharmacy workforce was a suggested hypothetical
facilitator [51, 54, 55, 59, 60, 68, 71, 74, 85], including
better collaboration between pharmacies [54], educa-
tional campaigns [71], mentoring and networking oppor-
tunities [55, 74], culture change [68], better advertising
[51, 85], and promotion [59, 60, 85].
Operationalisation of the innovation
Available resources Lack of time [6, 50–54, 57–61, 65,
68, 70–73, 75, 76, 79, 81, 83, 85, 87] and increased work-
load [50, 54, 61, 83, 84] associated with an innovation
were common. Issues included insufficient staffing [72,
73, 76, 78] and losing staff to training events [61], and
one study reported the benefits of having two pharmacists
on duty [74]. Two studies reported a general lack of oper-
ational resources [70, 79]. Studies mostly reported
innovation-specific barriers such as a lack of printers [65]
and reporting forms for adverse drug reporting [51, 58–
60, 85]. Lack of access to clinical information was cited for
both the legislative and clinical services [66, 67, 72, 78, 79]
as was a lack of suitable space [57, 72, 76, 78]. Two studies
cited adequate pharmacy facilities, such as a consultation
room [71, 73]. Six studies reported valued resources asso-
ciated with an innovation [57, 61, 62, 64, 71, 74], and nine
suggested resources which would facilitate implementa-
tion [6, 51, 55, 65, 72, 79, 81, 84, 87], including access to
clinical information about patients [79, 87], reporting
forms [50], improved IT systems [6, 55, 65, 79, 81], a
consultation area [71], and a “fact sheet” to facilitate
implementation [84].
Design quality and packaging Poor design was most
common amongst clinical services. This included the re-
quirement of patient consent devaluing the innovation
and patient’s perception of the pharmacist as a profes-
sional [56], being unaware of a patient’s discharge from
hospital [67], lapsing of customer registration [79], and
inappropriate patient referrals [55]. For a service where
medication information was legislated to be supplied to
all patients, information was not available in other lan-
guages and considered too long to print [65]. For a phar-
macovigilance program, centralisation of the reporting
system was a barrier [59]. Poor quality of the innovation
mainly pertained to IT or system issues [58, 61, 74, 78,
81] or the nature of the paperwork involved [58, 67].
Eleven studies suggested improvements to the design
and quality of the innovations [51, 55, 58–60, 64, 65, 67,
72, 85, 86].
Complexity Difficultly of an innovation [50, 56, 57, 63,
74, 78] and the complexity of its operationalisation were
reported [60, 78], with the latter most commonly relat-
ing to the complexity of the remuneration or reporting
processes [6, 51, 56, 59, 74, 85]. One study reported bar-
riers relating to the complexity of the implementation
process itself [84]. Three studies suggested simplifying
reporting procedures [51, 59, 85].
Compatibility—with systems Incompatibility with work
systems [65] or applicability in certain settings [57] was
reported. Three studies cited compatibility with working
systems as a facilitator [57, 71, 74], and work process
change was suggested in one study to facilitate [65].
Access to knowledge and information Two studies
cited training received to be useful [57, 86]; however, a
lack of appropriate training was cited by other partici-
pants for one of these studies [57]. Inadequacy of the
training was cited by five studies, including the training
not meeting the needs of staff [86], the lack of appropri-
ate training [55, 57, 71], or the training focusing on fill-
ing out forms rather than skills-based [87]. Whilst three
studies cited a lack of information available on the
innovation [57, 74, 79], four had participants comment
positively on information received [57, 62, 71, 78]. Better
access to information and training was a suggested hypo-
thetical facilitator reported by 17 studies [50, 51, 55, 57–
60, 62, 65, 68, 71, 74, 76, 77, 80, 84, 85], including sugges-
tions of continuous training [50, 51, 59, 60, 62], mentoring
and peer review [74], and incorporating training within
undergraduate pharmacy degrees [58, 60, 85].
External engagement
Cosmopolitanism Pharmacy staff perceived that other
healthcare professionals held negative views for the
legislative and clinical services. Seven studies cited nega-
tive response [6, 50, 52, 72, 74, 77, 79], which included
reluctance [50], lack of support [78], or general negative
views [6, 52, 72, 74, 77]. Lack of referral was a cited bar-
rier for clinical services [54, 55, 67, 77], and lack of
collaboration and communication with healthcare pro-
fessionals was also apparent [60, 71, 74, 77–79, 87].
Facilitators included doctor referrals [61], establishment
of new contacts [54], and having pre-existing relation-
ships with other healthcare professionals [77].
Patient needs and resources Although there were no
reports from studies evaluating pharmacovigilance inno-
vations within this construct, other innovation types had
numerous citations. Patient’s support and acceptance of the
innovation [75, 77, 80, 83] and positive feedback [54, 57,
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82, 83] were contrasted by negative perceptions [50, 52, 63,
75, 77, 78]. These included resistance to change or advice
[50, 63, 75, 78], perceiving the innovation as lacking in
value [77], and perceiving “pharmacists as drug suppliers
only” [52]. Two studies reported patient demand [55, 57];
however, pharmacy staff generally reported low public
demand [57, 62, 74, 77–79, 86] or that patients were un-
interested or reluctant [6, 65, 72, 77]. For the clinical ser-
vices, there was difficulty recruiting patients [56], reaching
targets [61, 77], and retaining patients [56], or patients
could not attend appointments [53, 74, 77]. One study
reported public awareness [57], yet lack of public know-
ledge or awareness was more commonly reported [54, 57,
61, 63, 64, 74, 77, 82].
Engaging stakeholders Although three studies cited
lack of advertising or promotion of the innovation as a
barrier to patient engagement [59, 74, 79], 12 studies
across all innovation types suggested better informing
and engaging patients [6, 50, 52, 54, 57, 61, 64, 65, 68,
76, 80, 85]. One study reported that banners and dis-
plays increased customer awareness [83]. Suggested fa-
cilitators included patient education programmes [64,
65, 79, 80] and local publicity and media campaigns [52,
54, 57, 61]. Five studies suggested better engagement
with other healthcare professionals [50, 64, 68, 74, 77].
Discussion
This systematic review evaluated heterogeneous inno-
vations to identify the factors influencing national im-
plementation within the community pharmacy setting.
Three key thematic areas were identified: (1) phar-
macy staff engagement with implemented innovations,
including staff perceptions and beliefs regarding the
innovation; (2) operationalisation of the innovation,
such as lack of resources; and (3) external
engagement with implemented innovations, including
perceived negative views of patients and other health-
care professionals. We discuss each in turn with cross
comparison to previous reviews conducted by Roberts
et al. [20] and Shoemaker et al. [21]. A comparison
of the emergent CFIR constructs with these reviews is
available in Additional file 6.
In relation to pharmacy staff engagement, mixed posi-
tive and negative perceptions of innovations by pharmacy
staff were apparent. This is in contrast to previous reviews
which found that pharmacists are generally favourable
towards new services [94] and that pharmacists’ positive
beliefs and attitudes about a service facilitate successful
implementation [20, 21]. This review’s findings may reflect
the inclusion of national innovations only, as barriers
emerging in small-scale pilot phases may not reflect the
barriers experienced following scale up [17].
Innovations were considered advantageous by pharmacy
staff if they enhanced the relationship with patients, im-
proved relationships with surrounding healthcare profes-
sionals, benefitted patients, or improved workforce
capability. Personal incentives included professional satis-
faction, recognition, and influence. Shoemaker et al.’s
review also identified that improving patients’ health and
relationship with the pharmacy was advantageous [21] and
that demonstration of skillset and perceived value to the
public was an incentive [21]. Shoemaker at al additionally
found the acquisition of new patients attending the phar-
macy to be a facilitator of implementation [21], and the
positive influence of monetary incentives and financial
betterment mirrors previous findings [20, 21]. These find-
ings highlight the challenge of balancing the professional,
clinical, and commercial obligations within the com-
munity pharmacy setting [95]. Although exploring
pre-implementation phases was outwith the scope of
this review, exploring the cognitive processes under-
pinning decisions to implement innovations in light
of financial and personal incentives, and how these
weigh against patient-related benefits, would be an in-
teresting area for future research [96].
The most commonly reported barrier in relation to the
operationalisation of an innovation was the lack of avail-
able resources (e.g. time and workload constraints) which
echoed Shoemaker et al.’s findings [21]. Beyond staff re-
cruitment, the promotion of whole-team engagement and
delegation of tasks to pharmacy support staff may facilitate
more efficient workflow [97–101] and practice change
[20]. Barriers relating to insufficient resources and training
were common, as was poor design, complexity, and incom-
patibly of the innovation, with the latter two also identified
by Shoemaker et al. [21]. “Bottom-up” implementation
strategies with front-line staff involved in the design and
testing of innovations may overcome resource insufficien-
cies and design flaws [102, 103].
External engagement centred on the perceptions of
other healthcare professionals and patients. Negative
perceptions of other healthcare professionals, and lack
of communication and collaboration with pharmacy
staff, was a barrier. Roberts et al. also identified that
communication with doctors and their attitudes influ-
enced successful implementation of cognitive pharmacy
services [20], whilst Shoemaker et al. identified cosmo-
politanism and engagement of the wider healthcare set-
ting to be a facilitator [21]. General practitioners have
previously reported lack of collaboration with commu-
nity pharmacies [104], with evidence that they are cau-
tious about their adoption of new services [105] and
clinical roles [106–109].
The influence of perceived patient acceptance was
also prominent—community pharmacy staff cited lack
of patient demand and their resistance towards
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innovations. Conversely, a review of patient-reported
satisfaction with community pharmacy services found
high satisfaction [110], and a disparity between how
pharmacists perceive patient satisfaction and how pa-
tients report satisfaction has been previously identi-
fied [111]. Shoemaker et al. identified patient demand
for vaccination services and acceptance of Medication
Therapy Management, with no barriers identified re-
lating to patient engagement [21]. Additionally, low
public awareness of innovations was commonly cited,
and there have been mixed findings in relation to
patient awareness of community pharmacies’ roles
[111–115]. Informing the public was a commonly re-
ported hypothetical facilitator, suggesting that poor
public engagement is perceived as a limitation of the
implementation strategies adopted.
Development of a preliminary theory and
recommendations for future research
A critical output of this systematic review was the iden-
tification of the three overarching thematic areas
(Table 5). The identification of these overarching the-
matic areas allowed for a preliminary causal theory to be
developed (Fig. 2). This was not an initial objective of
this review as per the initial PROSPERO record (Regis-
tration number: CRD42016038876). This preliminary
theory proposes that successful national implementation
of an innovation requires (1) the pharmacy staff to posi-
tively engage with an innovation, (2) the innovation to
be easily operational within community pharmacies, and
(3) the positive external engagement of patients and
other healthcare professionals. The authors view a com-
munity pharmacy-specific theory to be necessary due to
its distinctiveness when compared to other primary care
settings—for example, patients are able to consult with a
healthcare professional within community pharmacies
without the need for an appointment. Furthermore, the
theory presents the high-level influencers of successful
implementation within this setting, which may facilitate
evaluations if exploration of all 39 CFIR constructs is
not feasible.
Further work is needed to understand the interaction
between the three overarching thematic areas and to con-
sider how the influence of each may differ within varying
contexts and settings. Once tested further, applying this
theory at an early stage of an innovation’s implementation
process could inform potential refinements to an
innovation. As “External Engagement” was an emergent
theme, this exemplifies the impact of the surrounding
outer context and indicates that the community pharmacy
setting is not detached from the wider primary care set-
ting. Wider exploration of the perspectives of other
healthcare professionals and the public may strengthen
this understanding.
In line with previous work, this review identified that
adopted implementation strategies are poorly reported
in the literature [14, 21], and the development of innova-
tions was also poorly described. Future studies should
explicitly report the implementation strategies being
adopted and greater details of the innovation being im-
plemented, including its development, to allow for con-
sideration of how these aspects may influence successful
implementation [116, 117].
The emergent CFIR constructs identified in this review
complemented those from related reviews [20, 21],
which suggests our findings are valid. However, given
the methodological differences in the review approaches,
this should be interpreted with a degree of caution. Two
CFIR constructs cited by Shoemaker et al. and Roberts et
al. were not emergent in this review: “Culture” [20, 21] and
Fig. 2 Preliminary theory of the influences affecting the national implementation of community pharmacy innovations
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“Trialability” [21]. As Roberts et al. only reported “culture
in pharmacy” and did not elaborate, it was not possible to
consider why culture was reported in this previous review
and not in the current review. Shoemaker et al. coded
“alignment with missions/priorities” and “commitment to
providing preventive services” within “Culture”, which the
current authors would have coded within “Compatibility”
(i.e. how the innovation “aligns with individuals’ own norms
and values”) [37]. With regards to “Trialability”, Shoemaker
et al. identified that slow expansion of immunisation ser-
vices facilitated implementation, which would unlikely be
salient within scaled-up national services [21]. It was more
common for differences to emerge in the valence of the re-
ported CFIR constructs. For example, the current re-
view identified negative patient perceptions (patient
needs and resources) and lack of engagement of ex-
ternal healthcare professional (cosmopolitanism),
whereas Shoemaker et al. only reported facilitators
within these CFIR constructs [21]. This may suggest
that emergence of barriers and facilitators at national
level is comparable to those in small-scale pilot
stages, yet the strength of influence they have on
implementation may differ, which would be an inter-
esting area for further research.
Recommendations for future implementation strategies
From these findings, future implementation strategies
(Table 6) for national community pharmacy innovations
should involve the use of piloting strategies, promotion
of whole-team involvement, pre-implementation explor-
ation, and stakeholder engagement strategies.
Strengths and limitations
Alignment of the results to the CFIR positions the re-
search within the wider implementation science literature.
However, the inclusion of qualitative and quantitative
studies and the varying level of reporting detail meant it
was not possible to weight identified barriers and facilita-
tors and deduce relative influences. The results instead
reflected the number of reporting studies, which is not
uncommon for reviews of this nature [20, 21, 118–120].
Primary studies would benefit from applying the CFIR
“rating rules” which explore the valence (i.e. positive or
negative impact) and strength of influence of emergent
CFIR constructs [93]. Nevertheless, tabulation of the
results facilitated consideration of the relationship
between constructs and cross comparison [45].
The inclusion of qualitative, quantitative, and mixed
method studies ensured wide exploration of the barriers
and facilitators in this context, which meant that differ-
ent quality assessment tools were applied. Although
tools of similar depth were selected, it is notable that the
CASP and BGQC tools covered different aspects of
quality [26, 32]. For example, the BGQC tool does not
explore the relationship between participants and
researchers unlike the CASP tool. Therefore, to what ex-
tent the quality assessment results are truly comparable
between study types is unknown.
To the authors’ knowledge, using a directed content
analysis approach when applying the CFIR is novel
and helped assess its applicability to the community
pharmacy setting. The CFIR constructs captured most
emergent data except for two instances within the
CFIR outer setting domain. Patients’ perceptions,
awareness, and engagement were not encompassed
within the “Patient Needs and Resources” construct
as the construct focuses on the ability of an organisa-
tion to identify and prioritise patient’s needs (which
has been criticised elsewhere [121]). The “Cosmopolit-
anism” construct overlooks the impact of external
healthcare professional’s engagement as it centres on
networking with external organisations, and further
exploration of how cosmopolitanism may be influ-
enced by the infrastructure of healthcare systems is
required. Both of these factors would not appear rele-
vant in any other CFIR domain or construct, and we
suggest widening the scope of these CFIR constructs
accordingly.
Limiting the search to the English language compro-
mised the ability to identify implementation facilitators
and barriers internationally. However, 41% (n = 16) of in-
cluded studies were from non-English-speaking nations.
During full-text screening, 35 studies could not be
accessed. As only 8% (n = 29) of the 358 studies
screened were included, we estimate only three of these
would be eligible for inclusion. Although the study selec-
tion process underwent independent validation, align-
ment of the results to the CFIR was not conducted
independently. However, a dedicated CFIR codebook
and technical assistance guide was routinely accessed to
Table 6 Key recommendations for future national
implementation strategies within the community
pharmacy setting
1. Conduct more robust piloting of innovations to overcome operational
issues, for example, using “bottom-up” techniques. Phased
implementation strategies may facilitate scale-up, whereby innovations
are tested and iteratively re-designed in gradually larger settings. This
could ensure innovations are ready for mass application by testing their
feasibility and appropriateness in different contexts [17, 116, 117].
2. Promote whole-team involvement with innovations to overcome
resource barriers such as time and workload constraints.
3. Conduct pre-implementation exploration to identify training needs,
and to predict pharmacy staff acceptance of innovations by considering
if the innovation poses any of the advantages and incentives identified
within this review.
4. Develop more thorough stakeholder engagement strategies to
overcome barriers relating to acceptance of external healthcare
professionals and raise general public awareness of innovations and
acceptance through emphasis of intended benefits.
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ensure appropriate alignment to CFIR constructs [93].
Lower quality studies were retained to allow for broad
data capture, and removal of the lower quality studies
did not affect the representation of the most commonly
cited CFIR constructs. Conference abstracts obtained
the lowest quality scores—likely to be reflective of their
reporting depth—although retaining these ensured
representation of the latest research [120].
Conclusions
Pharmacy staff ’s perceptions of the barriers and facilita-
tors to the implementation of national innovations
within the community pharmacy setting have been
identified. Commonly reported factors which influence
implementation include insufficient resources, the
views of patients and other healthcare professionals,
pharmacy staff perceptions and acceptance of innova-
tions, and belief that innovations were beneficial. Key
findings led to the development of a preliminary theory
where it is proposed that successful national implemen-
tation of community pharmacy innovations requires in-
novations which are easy to operate, alongside
positively engaged patients, pharmacy staff, and other
healthcare professionals such as GPs. Potential applica-
tions of the results include better directed evaluations
and the development of implementation strategies
which overcome common barriers and exploit known
facilitators. Key recommendations include (1) more ro-
bust piloting and sufficient pre-implementation explor-
ation, (2) phased implementation, (3) promotion of
whole-team involvement, and (4) more thorough
engagement strategies.
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